Combining both is the worst thing you can do
In a Spanish hospital, a patient's bleeding lungs became the first confirmed vaping-linked pulmonary hemorrhage in the country — a single case that nonetheless shifted the weight of a long-running debate. For years, e-cigarettes had been positioned as a bridge away from tobacco's harms, but mounting cellular evidence and this clinical reality are forcing a harder question: safer than what, and for whom? Europe's response — a coordinated registry to track similar cases across the continent — reflects a growing recognition that the consequences of vaping, like the devices themselves, do not respect national borders.
- A patient hospitalized in Spain with lung bleeding has become an unwilling landmark — the first confirmed vaping-linked pulmonary hemorrhage in the country, and a case that reverberated immediately through European health institutions.
- Laboratory research is no longer abstract: e-cigarette components are causing measurable damage to lung cells, and for those who vape while still smoking, researchers warn the combined chemical assault is worse than either habit alone.
- The 'safer alternative' narrative that built the vaping industry is under direct pressure, as clinicians and researchers argue that harm reduction only holds if the substitute is genuinely less harmful — a claim the evidence is struggling to support.
- European health authorities are moving from reactive to coordinated, establishing a shared registry so that a case in Madrid can be cross-referenced with cases in Paris or Berlin, accelerating the detection of patterns and vulnerable populations.
- The central unanswered questions now driving policy are urgent and practical: How many cases have gone unconnected to vaping? Which products and users carry the greatest risk? And is the damage being done reversible at all?
A patient arrived at a Spanish hospital coughing blood. The diagnosis — pulmonary hemorrhage linked to vaping — was the first of its kind confirmed in Spain, and it landed with the force of a precedent. European health authorities moved quickly; within weeks, plans were forming for a coordinated continental registry to track similar cases and build a clearer picture of what e-cigarettes are doing to human lungs.
The case reignited a debate that had never fully settled. Vaping had long marketed itself as a safer exit from tobacco — a harm-reduction tool for smokers trying to quit. But the Spanish case, layered on top of growing laboratory evidence of cellular lung damage, demanded a harder look at that claim. Researcher Montse Bellver was direct: vaping alone carries real risk, but the most dangerous pattern is dual use — people who reduce their cigarettes but keep vaping, believing they are making a trade in their favor. They are not. Two different chemical sources of damage compound in ways that are only beginning to be mapped.
Dr. Valerio Perna urged appropriate caution — one case does not establish causation, and a single patient is not a pattern. But that caution was being overtaken by the accumulating weight of other evidence, and by the suspicion that more cases existed across Europe, simply unrecognized or unconnected to vaping as their cause.
The registry represents a strategic shift: rather than waiting for individual nations to gather enough data to draw conclusions in isolation, health systems are moving toward coordination. A case in Spain compared against cases in France, Germany, or Italy could reveal which products are most dangerous, which users are most vulnerable, and whether the harm is reversible. It is a practical answer to an uncomfortable truth — that vaping is not the safe passage out of smoking many believed it to be, but a different category of risk, capable of manifesting suddenly and seriously, as one patient in a Spanish hospital has already learned.
A patient in Spain arrived at a hospital with bleeding in the lungs. The diagnosis was clear: pulmonary hemorrhage linked to vaping. It was the first confirmed case of its kind in the country, and it landed like a stone in still water. Health authorities across Europe took notice. Within weeks, plans were underway to establish a coordinated registry—a system to track similar cases across the continent and build a clearer picture of what e-cigarettes can do to the human body.
The case reopened a debate that had been simmering for years. Vaping had marketed itself as a safer alternative to smoking, a way to quit or reduce cigarette use. But the Spanish case, combined with mounting laboratory evidence, suggested that claim needed serious revision. Researchers examining the cellular damage caused by e-cigarette components found measurable harm to lung tissue—the kind of damage that doesn't announce itself until something goes wrong.
Montse Bellver, a researcher at the Tobacco Control Unit, was blunt about the math: switching from cigarettes to vaping alone carried real risk. But the worst scenario, she emphasized, was when people did both—when they reduced their traditional smoking but kept vaping, thinking they were making a trade. That combination, she said, was worse than either habit alone. The body was absorbing damage from two different sources, two different sets of chemicals, two different mechanisms of harm.
Dr. Valerio Perna offered a more cautious reading. A single case of pulmonary hemorrhage, he noted, does not by itself prove causation. One patient does not establish a pattern. But that caution, reasonable as it sounded in isolation, was being overtaken by the weight of other evidence. The components in e-cigarettes were causing measurable cellular damage. The case in Spain was real. And across Europe, health systems were beginning to suspect there might be more cases they hadn't yet identified or connected to vaping.
The European registry represented a shift in approach. Instead of waiting for individual countries to accumulate enough data to draw conclusions, health authorities were moving toward coordination—a shared system where a case in Spain could be compared with cases in France, Germany, or Italy. It was a recognition that e-cigarettes had become a continental phenomenon, and so had their consequences. The registry would allow researchers to spot patterns faster, to understand which users were most vulnerable, which products posed the greatest risk, and whether the damage was reversible or permanent.
What made the Spanish case significant was not just that it happened, but that it forced a reckoning with the narrative that had surrounded vaping for the past decade. The devices had been presented as harm reduction—a way to help smokers quit. But harm reduction only works if the alternative is actually less harmful. The evidence now suggested that e-cigarettes carried their own distinct risks, independent of traditional smoking. And for people who did both, the risks compounded in ways that were only beginning to be understood.
The establishment of the European registry was a practical response to an uncomfortable reality: vaping was not the safe exit from smoking that many had believed it to be. It was a different kind of risk, one that could manifest in sudden, serious ways—like a patient coughing up blood in a Spanish hospital. The registry would help answer the questions that case had raised: How common was this? Who was most vulnerable? And what did it mean for the millions of people across Europe who had switched to e-cigarettes thinking they were making a safer choice?
Citas Notables
Reducing cigarettes while vaping is not less harmful; combining both is the worst scenario— Montse Bellver, Tobacco Control Unit researcher
A single case of pulmonary hemorrhage does not by itself establish causation— Dr. Valerio Perna
La Conversación del Hearth Otra perspectiva de la historia
Why does one case in Spain matter enough to trigger a European registry? Isn't that overreacting?
One case is a signal. It's the first time in Spain that a patient's bleeding lungs could be traced directly to vaping. That doesn't prove vaping causes hemorrhage in everyone—but it proves it can happen. And if it happened once, it could happen again, maybe in ways we haven't recognized yet.
But doctors like Perna are saying a single case doesn't establish causation. Isn't he right?
He's technically right. One case alone doesn't prove anything. But he's also missing the forest. We already know e-cigarette components damage lung cells in measurable ways. We already know people are using these devices by the millions. One case is the moment when the laboratory findings stop being abstract and become a person in a hospital bed.
So the registry is about connecting dots that might otherwise stay separate?
Exactly. If a similar case happens in Italy or France, a doctor there might not immediately think of vaping. They might file it away as an unusual case. But if there's a registry, suddenly you see the pattern. You see that it's not one isolated incident—it's a signal.
What about the people who switched to vaping to quit smoking? Are they in danger?
That's the hard part. If you smoked and switched entirely to vaping, you've probably reduced some harms. But you've taken on new ones. And if you're doing both—smoking and vaping—you're exposing yourself to damage from two different sources at once. That's the worst position to be in.
So harm reduction only works if the alternative is actually less harmful?
Right. And we're learning that vaping isn't the clear win it was marketed as. It's a different risk, not a lower one.